Compounds > sk&f-38393
Page last updated: 2024-10-21

sk&f-38393 and Hyperlipidemias

sk&f-38393 has been researched along with Hyperlipidemias in 2 studies

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393

Hyperlipidemias: Conditions with excess LIPIDS in the blood.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liang, Y1
Lubkin, M1
Sheng, H1
Scislowski, PW2
Cincotta, AH2
Zhang, Y1
Prevelige, R1
Phaneuf, S1

Other Studies

2 other studies available for sk&f-38393 and Hyperlipidemias

ArticleYear
Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice.
    Biochimica et biophysica acta, 1998, Oct-21, Volume: 1405, Issue:1-3

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Blood Glucose; Bromocriptine; C

1998
Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice.
    Metabolism: clinical and experimental, 1999, Volume: 48, Issue:8

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adipose Tissue; Animals; Bromocriptine;

1999